Vivo Capital Overview

  • Investor Type
  • Venture Capital
  • Status
  • Active
  • Professionals
  • 29
Professionals
  • Investments
  • 276
  • Portfolio
  • 67
  • Exits
  • 174
Exits

Vivo Capital General Information

Description

Founded in 1996, Vivo Capital is a healthcare-focused venture capital firm based in Palo Alto, California. The firm seeks to invest in biopharmaceuticals, specialty pharmaceuticals, medical devices, and other subsectors of healthcare and life sciences companies.

Contact Information

Formerly Known As
BioAsia Investments
Year Founded
1996
Investor Status
Actively Seeking New Investments
Primary Investor Type
Venture Capital
Other Investor Types
Growth/Expansion
Primary Office
  • 192 Lytton Avenue
  • Palo Alto, CA 94301
  • United States
+1 (650) 000-0000

Vivo Capital Investments (276)

Company Name Deal Date Deal Type Deal Size Industry Company Stage Lead Partner
RayzeBio 09-Jun-2021 Later Stage VC 00000 Drug Discovery Pre-Clinical Trials
00000000 00000000 27-May-2021 00000 00000 0000 Surgical Devices Generating Revenue 000000 0000000
0000 000000000000 26-May-2021 00000 00000 00000 Biotechnology Generating Revenue 0000 00
0000000 0000000000 25-May-2021 0000 0000 Biotechnology Generating Revenue
0000 0000000000 17-May-2021 0000 00000 Drug Discovery Clinical Trials - Phase 2 00000000 0000 00.0
0000 00000000000 10-May-2021 00000 00000 00000 Diagnostic Equipment Generating Revenue/Not Profitable 000000 0000000
0000000000 06-May-2021 00 000000000 0000 Other Devices and Supplies Generating Revenue 000000 0000000
000000 00000000 23-Apr-2021 00000 00000 Machinery (B2B) Generating Revenue
Satsuma Pharmaceuticals 31-Mar-2021 PIPE 0000 Pharmaceuticals Generating Revenue/Not Profitable
Immune-Onc Therapeutics 30-Mar-2021 Later Stage VC 000.00 Drug Discovery Clinical Trials - General
You’re viewing 10 of 276 investments. Get the full list »
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Vivo Capital Exits (174)

Company Name Exit Date Exit Type Exit Size
Impel NeuroPharma 22-Apr-2021 IPO 0000
000000 00000000000 26-Mar-2021 000 00000
0000000000 0000000 01-Mar-2021 000000000000000000 00000
0000000 24-Feb-2021 000000000000000000
0000 0000000000000 05-Feb-2021 000 00000
00000 000000000000 05-Feb-2021 000 00000
00000000 000000000 29-Jan-2021 0000000000
0000000 000 22-Jan-2021 000000 0000000000 00000
Gracell 08-Jan-2021 IPO 00000
ALX Oncology 10-Dec-2020 Public Investment 2nd Offering 00000
You’re viewing 10 of 174 exits. Get the full list »

Vivo Capital Fund Performance

Fund Name Vintage Size Dry Powder DPI RVPI TVPI IRR

This information is available in the PitchBook Platform. To explore Vivo Capital‘s full profile, request access.

Request a free trial

Vivo Capital Investments by Industry, Year, and Region

Investments by Industry

Investments by Year

Investments by Region

PitchBook’s data visualizations quickly surface an investor’s historical investments—showing a breakdown of activity by industry, year and region.

Request a free trial

Vivo Capital Team (52)

Name Title Deals Funds Boards Office
Daisy Xu Managing Director Palo Alto, CA
DanDan Dong Ph.D Managing Director 0 0 0 Palo Alto, CA
David Liu Ph.D Managing Director Palo Alto, CA
Gaurav Aggarwal MD Managing Director 0 0 0 Palo Alto, CA
Joseph Siletto Managing Director 0 0 0 Palo Alto, CA
You’re viewing 5 of 52 team members. Get the full list »

Vivo Capital Co-Investors (260)

Name With Exits Lead Partner Series Industry
OrbiMed 13 0 Series chart Industry bar
venBio 00 0 0 Series chart Industry bar
Cormorant Asset Management 00 0 0 Series chart Industry bar
RA Capital Management 00 0 0 Series chart Industry bar
Lilly Asia Ventures 00 0 Series chart Industry bar
You’re viewing 5 of 260 co-investors. Get the full list »